Companies / Acrivon Therapeutics, Inc. / Activity
Activity — Acrivon Therapeutics, Inc.
6 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 14, 2026 | Blume-Jensen Peter CEO | Buy | Common Stock | $82.1K | +49K +2.39% | 2,095,771 4.89% of shares | medium |
| Feb 21, 2026 | Blume-Jensen Peter CEO | Other | Common Stock | $21.8K | -14K -0.68% | 2,080,204 4.85% of shares | low |
| Feb 14, 2026 | Blume-Jensen Peter CEO | Other | Common Stock | $2.1K | -1K -0.06% | 2,094,469 4.89% of shares | low |
| Feb 14, 2026 | Blume-Jensen Peter CEO | Other | Common Stock | $944 | -579 -0.18% | 314,127 0.73% of shares | low |
| Mar 1, 2026 | Blume-Jensen Peter CEO | Grant | Stock Option (Right to Buy) | — | +185K | 185,495 0.43% of shares | low |
| Mar 1, 2026 | Blume-Jensen Peter CEO | Grant | Stock Option (Right to Buy) | — | +417K | 417,210 0.97% of shares | low |